AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35561331 — intervention group
Group type: EXPERIMENTAL
Intervention: Unresectable tumors
Number of subjects: 262
Study 35561331 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free status
Number of subjects: 262
Study 35561554 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 relaxometry measurement of periventricular gradient in early multiple sclerosis
Number of subjects: 191
Study 35561554 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 relaxometry measurement of periventricular gradient in progressive multiple sclerosis
Number of subjects: 191
Study 35561554 — intervention group
Group type: COMPARATOR
Intervention: T1 relaxometry measurement in healthy controls
Number of subjects: 191
Study 35561554 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 relaxometry measurement
Number of subjects: 191
Study 35562076 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-m gait speed intervention
Number of subjects: 0
Study 35562076 — intervention group
Group type: EXPERIMENTAL
Intervention: Global cognition intervention (3MSE)
Number of subjects: 0
Study 35562098 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted optical diagnosis
Number of subjects: 389
Study 35562664 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-technical skills (NTS) performance assessment using the modified Team Emergency Assessment Measure (TEAM) score
Number of subjects: 359
Study 35562664 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership in resuscitation situations
Number of subjects: 359
Study 35562729 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 24
Study 35562729 — intervention group
Group type: EXPERIMENTAL
Intervention: NitroPOHL
Number of subjects: 24
Study 35562729 — intervention group
Group type: COMPARATOR
Intervention: Baseline GBF
Number of subjects: 24
Study 35562735 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted preventive program (TOF pilot2 study)
Number of subjects: 4633
Study 35562737 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis group (PG)
Number of subjects: 79
Study 35562737 — intervention group
Group type: COMPARATOR
Intervention: Non-periodontitis group (NPG)
Number of subjects: 79
Study 35562750 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA-derived genomic markers
Number of subjects: 141
Study 35562750 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA fraction
Number of subjects: 141
Study 35562750 — intervention group
Group type: EXPERIMENTAL
Intervention: blood-based tumor mutation burden (bTMB)
Number of subjects: 141
Study 35562784 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Jyvaskyla Active Aging Scale (UJACAS)
Number of subjects: 820
Study 35562794 — intervention group
Group type: EXPERIMENTAL
Intervention: AX (Arachidonic Acid)
Number of subjects: 0
Study 35562794 — intervention group
Group type: COMPARATOR
Intervention: MCC (Microcrystalline Cellulose)
Number of subjects: 0
Study 35565812 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE) regimen for 4 weeks
Number of subjects: 9
Study 35565812 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE) regimen
Number of subjects: 9
Study 35566502 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal cycle ergometer protocol (CPET)
Number of subjects: 80
Study 35566502 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, time since COVID-19, hospitalization, dizziness, joint pain, pre-existing cardiopulmonary disease, use of beta blockers
Number of subjects: 80
Study 35566586 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSA (AHI ≥30 events/h)
Number of subjects: 147
Study 35566586 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe OSA (AHI 15.0−29.9 and ≥30 events/h)
Number of subjects: 147
Study 35566586 — intervention group
Group type: COMPARATOR
Intervention: No-OSA (AHI <5.0 events/h)
Number of subjects: 147
Study 35567345 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of nusinersen
Number of subjects: 0
Study 35567345 — intervention group
Group type: COMPARATOR
Intervention: 12 mg dose of nusinersen
Number of subjects: 0
Study 35567422 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam, orally once daily for a median duration of 4.8 months (range, 0.3-9.2 months)
Number of subjects: 155
Study 35567560 — intervention group
Group type: EXPERIMENTAL
Intervention: sLOX-1 levels in ACS patients
Number of subjects: 2924
Study 35567560 — intervention group
Group type: EXPERIMENTAL
Intervention: sLOX-1 levels in ACS patients (T3)
Number of subjects: 2924
Study 35567560 — intervention group
Group type: EXPERIMENTAL
Intervention: sLOX-1 levels in ACS patients undergoing serial intracoronary imaging and statin therapy
Number of subjects: 2924
Study 35567559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow activation (BM 18F-FDG uptake above the median maximal standardized uptake value)
Number of subjects: 745
Study 35567559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow activation
Number of subjects: 745
Study 35567559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow activation and arterial 18F-FDG uptake
Number of subjects: 745
Study 35567614 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech features combined with demographics
Number of subjects: 103
Study 35567655 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPS scoring model (total score, 0-7 points) based on early brain injury indicators.
Number of subjects: 825
Study 35567655 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model for predicting outcomes.
Number of subjects: 825
Study 35567655 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration of the prediction model.
Number of subjects: 825
Study 35567671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks (q4w)
Number of subjects: 294
Study 35567671 — intervention group
Group type: EXPERIMENTAL
Intervention: Uptitration to approved dupilumab dose regimen (200 or 300 mg every 2 weeks)
Number of subjects: 294
Study 35567671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 294
Study 35567877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative indocyanine green (ICG) test during LSG
Number of subjects: 1
Study 35567877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative indocyanine green (ICG) test
Number of subjects: 1
Study 35567881 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (ML) analysis applied to 3D maxillofacial shapes
Number of subjects: 280
Study 35567881 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D geometric morphometrics combined with ML
Number of subjects: 280
Study 35567881 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 280
Study 35567913 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF V600E+ with BRCA1 or BRCA2 co-mutations (3 patients identified from MTB registry)
Number of subjects: 36966
Study 35567913 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF V600E+ MSS patients
Number of subjects: 36966
Study 35567913 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF V600E+ MSS patients with BRCA co-mutations
Number of subjects: 36966
Study 35567914 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (P+AI)
Number of subjects: 170
Study 35567914 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant (P+F)
Number of subjects: 170
Study 35567914 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line palbociclib combinations
Number of subjects: 170
Study 35567914 — intervention group
Group type: EXPERIMENTAL
Intervention: Second- or later-line palbociclib combinations
Number of subjects: 170
Study 35568047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of bone marrow-derived allogeneic mesenchymal stromal cells (MSCs)
Number of subjects: 10
Study 35568510 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot popliteal sciatic nerve block
Number of subjects: 1365
Study 35568510 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable risk prediction model
Number of subjects: 1365
Study 35568651 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise pulmonary hypertension (ePH) group
Number of subjects: 40
Study 35568651 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-capillary pulmonary hypertension (postC PH) group
Number of subjects: 40
Study 35568651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-capillary pulmonary hypertension (preC PH) group
Number of subjects: 40
Study 35568651 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hemodynamics group
Number of subjects: 40
Study 35568651 — intervention group
Group type: EXPERIMENTAL
Intervention: ePH and PH groups
Number of subjects: 40
Study 35568651 — intervention group
Group type: EXPERIMENTAL
Intervention: ePH, preC-PH and postC-PH groups
Number of subjects: 40
Study 35568709 — intervention group
Group type: EXPERIMENTAL
Intervention: Variational autoencoder (VAE) with two latent variables
Number of subjects: 13580
Study 35568815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytic treatments
Number of subjects: 1380
Study 35568815 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased use of anxiolytics and SSRIs
Number of subjects: 1380
Study 35568815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety-like behavior
Number of subjects: 1380
Study 35568815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety as a concern
Number of subjects: 1380
Study 35568815 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication logs
Number of subjects: 1380
Study 35568881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone treatment
Number of subjects: 66
Study 35568903 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level academic detailing (AD)
Number of subjects: 36
Study 35568903 — intervention group
Group type: COMPARATOR
Intervention: AD plus the team-based Learn. Engage. Act. (LEAP) quality improvement (QI) learning program
Number of subjects: 36
Study 35568909 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision cancer drugs through IMPRESS-Norway
Number of subjects: 0
Study 35568909 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular diagnostics funded by the public health care system
Number of subjects: 0
Study 35568909 — intervention group
Group type: COMPARATOR
Intervention: Targeted therapies
Number of subjects: 0
Study 35569489 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake craniotomy
Number of subjects: 1047
Study 35569802 — intervention group
Group type: EXPERIMENTAL
Intervention: gefapixant, a P2 × 3-receptor antagonist
Number of subjects: 2044
Study 35570015 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.96% zinc (zinc oxide, zinc citrate) in a silica base (Test 1)
Number of subjects: 83
Study 35570015 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.454% SnF (Test 2)
Number of subjects: 83
Study 35570249 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 35570249 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 0
Study 35570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CYP1A2)
Number of subjects: 36
Study 35570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (CYP2B6)
Number of subjects: 36
Study 35570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (CYP2C9)
Number of subjects: 36
Study 35570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (CYP2C19)
Number of subjects: 36
Study 35570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (CYP2D6)
Number of subjects: 36
Study 35570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A)
Number of subjects: 36
Study 35570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic ratio for paraxanthine/caffeine (CYP1A2)
Number of subjects: 36
Study 35570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic ratio for 8-hydroxyefavirenz/efavirenz (CYP2B6)
Number of subjects: 36
Study 35570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic ratio for 5-hydroxyomeprazole/omeprazole (CYP2C19)
Number of subjects: 36
Study 35570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic ratio for α-hydroxymetoprolol/metoprolol (CYP2D6)
Number of subjects: 36
Study 35570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic ratio for 1'-hydroxymidazolam/midazolam (CYP3A)
Number of subjects: 36
Study 35570280 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2-I)
Number of subjects: 583
Study 35570280 — intervention group
Group type: COMPARATOR
Intervention: Other oral anti-diabetic agents (non-SGLT2-I)
Number of subjects: 583
Study 35570301 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-oriented home rehabilitation (TOHR)
Number of subjects: 12
Study 35570383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg) combined with aspirin
Number of subjects: 0
Study 35570383 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 35570383 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 35570651 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-State Functional Magnetic Resonance Imaging
Number of subjects: 0
Study 35570723 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs/symptoms of COVID-19 (fever, cough, dyspnea, atypical symptoms, delirium)
Number of subjects: 981
Study 35570723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 981
Study 35570723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachypnea
Number of subjects: 981
Study 35570723 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oxygen saturation
Number of subjects: 981
Study 35570723 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium
Number of subjects: 981
Study 35570846 — intervention group
Group type: EXPERIMENTAL
Intervention: Plexin-B2 knockdown
Number of subjects: 0
Study 35570983 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS649 0.5 mg/kg
Number of subjects: 51
Study 35570983 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS649 2.0 mg/kg
Number of subjects: 51
Study 35570983 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS649 6.0 mg/kg
Number of subjects: 51
Study 35570983 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS649 12.0 mg/kg
Number of subjects: 51
Study 35570983 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS649 6.0 mg/kg + vaccine
Number of subjects: 51
Study 35570983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 35570983 — intervention group
Group type: COMPARATOR
Intervention: Placebo + vaccine
Number of subjects: 51
Study 35570989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin treatment
Number of subjects: 14
Study 35571041 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Newborn Screening
Number of subjects: 0
Study 35571041 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn Genomic Sequencing
Number of subjects: 0
Study 35571196 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer drug-eluting stents (BP-DES)
Number of subjects: 127731
Study 35571196 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer drug-eluting stents (DP-DES)
Number of subjects: 127731
Study 35571641 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant SBRT followed by surgical resection
Number of subjects: 39
Study 35571881 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein, Low Glycemic Index (HPLG) dietary intervention
Number of subjects: 63
Study 35571881 — intervention group
Group type: COMPARATOR
Intervention: Balanced diet control group
Number of subjects: 63
Study 35571890 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal
Number of subjects: 36
Study 35571890 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid meal
Number of subjects: 36
Study 35571902 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 22
Study 35571902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 35571928 — intervention group
Group type: EXPERIMENTAL
Intervention: IQP-AE-103 (proprietary combination of dehydrated okra powder and inulin)
Number of subjects: 72
Study 35571928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 35571933 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-nutrient fortified dairy-based drink
Number of subjects: 0
Study 35572309 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner Engineering Completion Online (IECO) intervention, which includes a 21-min meditation practice called Shambhavi Mahamudra Kriya.
Number of subjects: 68
Study 35572519 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric Ketogenic Diet (75% fat, 20% protein, 5% carbohydrate) for 3 days
Number of subjects: 15
Study 35572740 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-I nasal irrigation (NI) at diluted concentrations of 0.4%
Number of subjects: 189
Study 35572740 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-I nasal irrigation (NI) at diluted concentrations of 0.5%
Number of subjects: 189
Study 35572740 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-I nasal irrigation (NI) at diluted concentrations of 0.6%
Number of subjects: 189
Study 35572740 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-I nasal spray (NS) at diluted concentrations of 0.5%
Number of subjects: 189
Study 35572740 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-I nasal spray (NS) at diluted concentrations of 0.6%
Number of subjects: 189
Study 35572740 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 189
Study 35572990 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 1399
Study 35572990 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 1399
Study 35573002 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for chronic-active antibody-mediated rejection (caABMR)
Number of subjects: 16
Study 35573309 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Number of subjects: 75
Study 35573309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 35573377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA)
Number of subjects: 0
Study 35573377 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone and smartwatch sensor data
Number of subjects: 0
Study 35573377 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media data
Number of subjects: 0
Study 35573377 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health records (EHR) data
Number of subjects: 0
Study 35574003 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin
Number of subjects: 393
Study 35574003 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin
Number of subjects: 393
Study 35574368 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy (NACT)
Number of subjects: 75
Study 35574368 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy (NACRT)
Number of subjects: 75
Study 35574368 — intervention group
Group type: COMPARATOR
Intervention: Control (NACT)
Number of subjects: 75
Study 35574368 — intervention group
Group type: COMPARATOR
Intervention: Control (NACRT)
Number of subjects: 75
Study 35574391 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent scalp-sparing radiation (60 Gy in 30 fractions) with TMZ (75 mg/m²)
Number of subjects: 30
Study 35574426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily (b.d.)
Number of subjects: 593
Study 35574426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (b.d.)
Number of subjects: 593
Study 35574426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study 35574491 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35574651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 35574651 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35574956 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-enhanced CA-AKI model including osteopontin and cystatin C
Number of subjects: 1114
Study 35574956 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney injury molecule-1 and interleukin-18
Number of subjects: 1114
Study 35575302 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive measurement using near infrared spectroscopy (NIRS)
Number of subjects: 40
Study 35575302 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive measurement of oxygen delivery (DO2)
Number of subjects: 40
Study 35575302 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive measurement of oxygen consumption (VO2)
Number of subjects: 40
Study 35575302 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive measurement of oxygen extraction ratio (O2ER)
Number of subjects: 40
Study 35575302 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of SveO2 and NIRS
Number of subjects: 40
Study 35575381 — intervention group
Group type: EXPERIMENTAL
Intervention: S predicted-progression score
Number of subjects: 0
Study 35575381 — intervention group
Group type: EXPERIMENTAL
Intervention: P predicted-progression score
Number of subjects: 0
Study 35575445 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of Smartphone Impact Scale (SIS-T)
Number of subjects: 264
Study 35575445 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of Smartphone Addiction Scale (SAS-T)
Number of subjects: 264
Study 35575702 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral flexibility assessed via the Do Something Different Questionnaire
Number of subjects: 387
Study 35575702 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behaviors assessed via HPLP-II at baseline, 3 months, and 6 months
Number of subjects: 387
Study 35575974 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV vaccine (TETRAXIM™)
Number of subjects: 647
Study 35576349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate with adjunct Misoprostol
Number of subjects: 0
Study 35576349 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0